Page 19 Volume 17 - N.4 - 2009

Dor (2009) 17
21. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve achalasia. Patient choice and treatment outcomes. Surg Endosc.
terminal remodeling unveiled using SNARE-cleaving botulinum tox- 1999;13:742-6.
ins: the extent and duration are dictated by the sites of SNAP-25 35. Brisinda G, Maria G, Bentivoglio AR. A comparison of injections of
truncation. Mol Cell Neurosci. 2003;22:454-66. botulinum toxin and topical nitroglycerin ointment for the treatment
22. De Andrés J, Cerda-Olmedo G, Valía JC, Monsalve V, Lopez-Alarcón, of chronic anal fissure. N Engl J Med. 1999;341:118-20.
Minguez A. Use of botulinum toxin in the treatment of chronic myo- 36. Castro M, Cánovas L, García-Rojo B, Morillas P, Martínez-Salgado
fascial pain. Clin J Pain. 2003;19:269-75. J, Gómez-Pombo A. Tratamiento del síndrome de dolor miofascial
23. Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther con toxina botulínica tipo A. Rev Soc Esp Dolor. 2006; 2:96-102.
1996;72:13-24. 37. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A
24. Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: induces direct analgesic effects in chronic neuropathic pain. Ann
Marcel Dekker, Inc; 1994. Neurol. 2009;65(3):359.
25. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for 38. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration
botulinum neurotoxin A. Science. 2006;312. of botulinum toxin A reduces formalin-induced pain. Pain. 2004;
26. Harvey AL. Presynaptics toxins. In: Smythies JR, Bradley RJ, eds. 107:125-33.
International review of neurobiologic. Vol 32. San Diego, CA: Aca- 39. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin - from labora-
demic Press; 1990. p. 201-39. tory to bedside. Neurotox Res. 2006;9:133-40.
27. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin- 40. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuro-
therapy, immunologic resistance, problems with available materials. pathic pain. A randomized double-blind crossover trial. Neurology.
Neurology. 1996;46:26-9. 2009;72:1473-8.
28. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botu- 41. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y.
linum neurotoxin poisoning. Prog Neurobiol. 1995;46:83-96. Comparison of lidocaine injection, botulinum toxin injection, and dry
29. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intra- needling to trigger points in myofascial pain syndrome. Rheumatol
fusal muscle effects in experimental botulinum toxin-A injection. Int. 2005;25:604-11.
Muscle Nerve. 1996;19:488-96. 42. Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for
30. Pleguezuelos Cobo E, Merí Vived A, Guirao Cano L, Moreno Atana- chronic non-malignant musculoskeletal pain: a systematic review.
sio E, Pérez Mesquida ME, Sanz Cartagena P. Atlas de puntos clave Pain Med. 2009;10:54-69.
musculares en la práctica clínica. Médica Panamericana (Madrid): 43. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger
2008;1-13. point injection technique for the treatment of cervicothoracic myo-
31. Scott AB, Kennedy RA, Stubbs MA. Botulinum A toxin injection as a fascial pain with botulinum toxin type A. Anesthesiology.
treatment for blepharospasm. Arch Ophthalmol. 1985;103:347-50. 2005;103:377-83.
32. Carruthers J, Carruthers A. The adjunctive usage of botulinum toxin. 44. Lew HL, Lee EH, Castaneda A, Klima R, Date E. Therapeutic use of
Dermatol Surg. 1998;24:1244-7. botulinum toxin type A in treating neck and upper-back pain of myo-
33. Matarasso SL. Complications of botulinum A exotoxin for hyperfunc- fascial origin: a pilot study. Arch Phys Med Rehabil. 2008; 89:75-80.
tional lines. Dermatol Surg. 1998;24:1249-54. 45. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Bot-
34. Andrews CN, Anvari M, Dobranowsi J. Laparoscopic Heller’s myo- ulinum toxin type A use in piriformis muscle syndrome: a pilot study.
tomy or botulinum toxin injection for management of esophageal Am J Phys Med Rehabil. 2002;81:751-9.

DOR

18